pCMV-Neo-Bam p53 R248W Citations (15)
Originally described in: Suppression of human colorectal carcinoma cell growth by wild-type p53.Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B Science. 1990 Aug 24. 249(4971):912-5. PubMed Journal
Articles Citing pCMV-Neo-Bam p53 R248W
| Articles |
|---|
| Cellular stress induced alterations in microRNA let-7a and let-7b expression are dependent on p53. Saleh AD, Savage JE, Cao L, Soule BP, Ly D, DeGraff W, Harris CC, Mitchell JB, Simone NL. PLoS One. 2011;6(10):e24429. doi: 10.1371/journal.pone.0024429. Epub 2011 Oct 11. PubMed |
| LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Mao XG, Hutt-Cabezas M, Orr BA, Weingart M, Taylor I, Rajan AK, Odia Y, Kahlert U, Maciaczyk J, Nikkhah G, Eberhart CG, Raabe EH. Oncotarget. 2013 Jul;4(7):1050-64. PubMed |
| Expression of galectin-7 is induced in breast cancer cells by mutant p53. Campion CG, Labrie M, Lavoie G, St-Pierre Y. PLoS One. 2013 Aug 14;8(8):e72468. doi: 10.1371/journal.pone.0072468. eCollection 2013. PubMed |
| Expression and functions of galectin-7 in ovarian cancer. Labrie M, Vladoiu MC, Grosset AA, Gaboury L, St-Pierre Y. Oncotarget. 2014 Sep 15;5(17):7705-21. PubMed |
| DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. Hanaford AR, Archer TC, Price A, Kahlert UD, Maciaczyk J, Nikkhah G, Kim JW, Ehrenberger T, Clemons PA, Dancik V, Seashore-Ludlow B, Viswanathan V, Stewart ML, Rees MG, Shamji A, Schreiber S, Fraenkel E, Pomeroy SL, Mesirov JP, Tamayo P, Eberhart CG, Raabe EH. Clin Cancer Res. 2016 Mar 24. PubMed |
| Cadherin-6 type 2, K-cadherin (CDH6) is regulated by mutant p53 in the fallopian tube but is not expressed in the ovarian surface. Karthikeyan S, Lantvit DD, Chae DH, Burdette JE. Oncotarget. 2016 Oct 25;7(43):69871-69882. doi: 10.18632/oncotarget.11499. PubMed |
| Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia. Gopalakrishnapillai A, Kolb EA, McCahan SM, Barwe SP. Leuk Res. 2017 Jul;58:91-97. doi: 10.1016/j.leukres.2017.05.004. Epub 2017 May 5. PubMed |
| Development of a genetic sensor that eliminates p53 deficient cells. Mircetic J, Dietrich A, Paszkowski-Rogacz M, Krause M, Buchholz F. Nat Commun. 2017 Nov 13;8(1):1463. doi: 10.1038/s41467-017-01688-w. PubMed |
| Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. Schulz-Heddergott R, Stark N, Edmunds SJ, Li J, Conradi LC, Bohnenberger H, Ceteci F, Greten FR, Dobbelstein M, Moll UM. Cancer Cell. 2018 Aug 13;34(2):298-314.e7. doi: 10.1016/j.ccell.2018.07.004. PubMed |
| p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT. Yang-Hartwich Y, Tedja R, Roberts CM, Goodner-Bingham J, Cardenas C, Gurea M, Sumi NJ, Alvero AB, Glackin CA, Mor G. Mol Cancer Res. 2019 Jan;17(1):153-164. doi: 10.1158/1541-7786.MCR-18-0238. Epub 2018 Aug 21. PubMed |
| p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition. Aggarwal M, Saxena R, Asif N, Sinclair E, Tan J, Cruz I, Berry D, Kallakury B, Pham Q, Wang TTY, Chung FL. J Exp Clin Cancer Res. 2019 Jul 15;38(1):307. doi: 10.1186/s13046-019-1267-z. PubMed |
| Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. Hanaford AR, Alt J, Rais R, Wang SZ, Kaur H, Thorek DLJ, Eberhart CG, Slusher BS, Martin AM, Raabe EH. Transl Oncol. 2019 Oct;12(10):1314-1322. doi: 10.1016/j.tranon.2019.05.013. Epub 2019 Jul 21. PubMed |
| Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. Palanikumar L, Karpauskaite L, Al-Sayegh M, Chehade I, Alam M, Hassan S, Maity D, Ali L, Kalmouni M, Hunashal Y, Ahmed J, Houhou T, Karapetyan S, Falls Z, Samudrala R, Pasricha R, Esposito G, Afzal AJ, Hamilton AD, Kumar S, Magzoub M. Nat Commun. 2021 Jun 25;12(1):3962. doi: 10.1038/s41467-021-23985-1. PubMed |
| Deficient or R273H and R248W Mutations of p53 Promote Chemoresistance to 5-FU via TCF21/CD44 Axis-Mediated Enhanced Stemness in Colorectal Carcinoma. Gao X, Zheng X, Zhang Y, Dong L, Sun L, Zhao N, Ding C, Ma Z, Wang Y. Front Cell Dev Biol. 2022 Jan 5;9:788331. doi: 10.3389/fcell.2021.788331. eCollection 2021. PubMed |
| Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis. Iwahashi N, Ikezaki M, Komohara Y, Fujiwara Y, Noguchi T, Nishioka K, Sakai K, Nishio K, Ueda M, Ihara Y, Uchimura K, Ino K, Nishitsuji K. PNAS Nexus. 2022 Jul 25;1(3):pgac128. doi: 10.1093/pnasnexus/pgac128. eCollection 2022 Jul. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.